The 2nd Neuroscience Innovation Partnering & Licensing Summit is built to accelerate deal-making in neuroscience.
This guide outlines licensing trends, asset valuation strategies, and collaboration models connecting biotech innovators with pharma and investors across CNS indications.
Key themes include:
- Neuroscience licensing and deal structures
- Asset valuation and portfolio strategy
- Early-stage innovation and translation
- Cross-sector partnering models
About Hanson Wade Group - 2nd Neuroscience Innovation Partnering & Licensing
Advance Best- or First- in Class Candidates, Raise Capital & Drive Disease Modification
From transformative genetic therapies in rare diseases to neuroimmunology candidates addressing residual unmet needs in MS, and novel target validation driving confidence in disease modification for neurodegeneration, best- and first-in-class neuroscience opportunities continue to shape and drive pharma investment.
Returning for its second year, following the inaugural launch that attracted over 100 attendees, the 2nd Neuroscience Innovation Partnering & Licensing Summit is strategically timed to facilitate multiple high-impact, in-person meetings without the distractions of a broader, less focused setting.
Who Attends This Differentiated Business Development Initiative?
- Global Pharma: Heads of Business Development, Search & Evaluation, and Asset Scouting for Neuroscience - comparing pipelines and enabling technologies to fuel future innovation.
- Innovative Biotech: C-level executives and BD leaders across neurodegeneration, psychiatry, neuro-oncology, and pain - seeking feedback, validation, and strategic partnerships with pharma and investors.
- Investors & Venture Capital: Leaders focused on neuroscience investments with higher risk appetite - looking for insights into pharma strategy and access to breakthrough opportunities.
Less competitive and more accessible, pharma can assess related programs back-to-back, while biotech has a protected opportunity to meet multiple big pharma players against the backdrop of market intelligence.
Download the Event Guide
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.net, which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.